Ahead of their presentations at ASHG next week, we take a look at what genomic big data specialists WuXi NextCODE are all about.

At the start of this year, WuXi NextCODE appeared on the international genomics scene after Chinese CRO WuXi Pharma Tech acquired NextCODE Health. Since then the company has been working hard, forming international partnerships designed to drive forward genomic medicine. In June this year they partnered with Genomics England to provide clinical interpretation for whole genome sequences of patients involved in the 100,000 Genomes Project, and a new partnership with Fudan Children’s Hospital looks set to advance the presence of precision medicine in China. 

“WuXi NextCODE is powering precision medicine worldwide, with comprehensive genomics capabilities and services,” said the company in a statement. These include:

  • CLIA Sequencing
  • Secondary analysis
  • HIPAA-compliant cloud storage
  • Sequence-based diagnostics
  • Large-scale research
  • Drug target discovery

“We’re serving the preeminent diagnostic enterprises, research hospitals, population genomics programs and pharmaceutical companies – and we want to empower you, too.”

At this year’s ASHG Annual Meeting WuXi NextCODE will be involved in two sessions exploring how to make the most of large next generation sequencing datasets.

Learn more at:

Genomes for Breakfast: A Technical Deep-dive into the Most Powerful System for Mining and Collaborating with Large-scale NGS and Phenotype Data. Wednesday, Oct. 7, 7:15-8:45am, Baltimore Convention Center, Room 336, Level 3

Big Genomics in Practice: The Integrated and Efficient Use of Massive NGS Data for Diagnostics and Discovery. Thursday, Oct. 8, 1:00-2:30pm, Sheraton Inner Harbor Hotel, Chesapeake Ballroom I, 3rd Floor

Find WuXi NextCODE at ASHG Booth #717

Find out more about their ASHG activities at wuxinextcode.com/ashg

More on these topics